How many insider trades does FilingIQ track for INAB?

FilingIQ tracks 108 Form 4 insider transactions for INAB (IN8BIO, INC.), covering filings from Aug 3, 2021 onwards. 9 of those were filed in the last 90 days.

Are INAB insiders net buyers or net sellers?

Across the full Form 4 history for INAB, 49 transactions (45%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does INAB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is INAB in?

IN8BIO, INC. (INAB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $17.01M.

INAB insider trading

Healthcare

IN8BIO, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

108

Last 90 days

Buys / sells

45% / 0%

Market cap

$17.01M

About IN8BIO, INC.

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

Company website: in8bio.com

INAB insider activity at a glance

FilingIQ has scored 108 insider transactions for INAB since Aug 3, 2021. The most recent filing in our index is dated May 9, 2026.

Across the full history, 49 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on INAB insider trades is 57.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live INAB trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for INAB?: FilingIQ tracks 108 Form 4 insider transactions for INAB (IN8BIO, INC.), covering filings from Aug 3, 2021 onwards. 9 of those were filed in the last 90 days.
Are INAB insiders net buyers or net sellers?: Across the full Form 4 history for INAB, 49 transactions (45%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does INAB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is INAB in?: IN8BIO, INC. (INAB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $17.01M.

Methodology & sources

Every INAB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.